Market revenue in 2023 | USD 272.4 million |
Market revenue in 2030 | USD 764.4 million |
Growth rate | 15.9% (CAGR from 2023 to 2030) |
Largest segment | (crispr)/cas9 |
Fastest growing segment | (CRISPR)/Cas9 |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
(crispr)/cas9 was the largest segment with a revenue share of 46.4% in 2024. Horizon Databook has segmented the Spain genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
Growing adoption of advanced genome editing technology to cure several diseases, such as cancer, infectious diseases, and genetic disorders, is expected to drive the market growth. For instance, in 2020, Spanish National Cancer Research Center (CNIO) researchers successfully destroyed Ewing’s sarcoma and chronic myeloid leukemia tumor cells by utilizing CRISPR genome editing technology to cut out the fusion gene that causes the development of cancer cells.
This was the first time that fusion genes were efficiently and selectively eliminated utilizing CRISPR genome editing technology. This factor is expected to open avenues for the development of cancer therapies.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account